Pentose-phosphate pathway disruption in the pathogenesis of Parkinson’s disease

Healy D.G., Falchi M., O’Sullivan S.S., Bonifati V., Durr A., Bressman S., et al., Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study, Lancet Neurol., 2008, 7, 583–590 Surmeier D.J., Guzman J.N., Sanchez-Padilla J., Goldberg J.A., The origins of oxidant stress in Parkinson’s disease and therapeutic strategies, Antioxid. Redox Signal., 2011, 14, 1289–1301 Hurtig H.I., Trojanowski J.Q., Galvin J., Ewbank D., Schmidt M.L., Lee V.M., et al., Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease, Neurology, 2000, 54, 1916–1921 Dias V., Junn E., Mouradian M.M., The role of oxidative stress in Parkinson’s disease, J. Parkinsons Dis., 2013, 3, 461–491 Alam Z.I., Daniel S.E., Lees A.J., Marsden D.C., Jenner P., Halliwell B., A generalised increase in protein carbonyls in the brain in Parkinson’s but not incidental Lewy body disease, J. Neurochem., 1997, 69, 1326–1329 Jenner P., Oxidative stress in Parkinson’s disease, Ann. Neurol., 2003, 53(Suppl. 3), S26–S36, discussion S36–38 Ben-Yoseph O., Boxer P.A., Ross B.D., Oxidative stress in the central nervous system: monitoring the metabolic response using the pentose phosphate pathway, Dev. Neurosci., 1994, 16, 328–336 Salvemini F., Franzé A., Iervolino A., Filosa S., Salzano S., Ursini M.V., Enhanced glutathione levels and oxidoresistance mediated by increased glucose-6-phosphate dehydrogenase expression, J. Biol. Chem., 1999, 274, 2750–2757 Pandolfi P.P., Sonati F., Rivi R., Mason P., Grosveld F., Luzzatto L., Targeted disruption of the housekeeping gene encoding glucose 6-phosphate dehydrogenase (G6PD): G6PD is dispensable for pentose synthesis but essential for defense against oxidative stress, EMBO J., 1995, 14, 5209–5215 Dunn L., Allen G.F., Mamais A., Ling H., Li A., Duberley K.E., et al., Dysregulation of glucose metabolism is an early event in sporadic Parkinson’s disease, Neurobiol. Aging, 2014, 35, 1111–1115 Bolanos J.P., Heales S.J., Persistent mitochondrial damage by nitric oxide and its derivatives: neuropathological implications, Front. Neuroenergetics, 2010, 2, 1 Herrero-Mendez A., Almeida A., Fernández E., Maestre C., Moncada S., Bolaños J.P., The bioenergetic and antioxidant status of neurons is controlled by continuous degradation of a key glycolytic enzyme by APC/C-Cdh1, Nat. Cell Biol., 2009, 11, 747–752 Pellerin L., Magistretti P.J., Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization, Proc. Natl. Acad. Sci. USA, 1994, 91, 10625–10629 Tsacopoulos M., Magistretti P.J., Metabolic coupling between glia and neurons, J. Neurosci., 1996, 16, 877–885 Stokes A.H., Hastings T.G., Vrana K.E., Cytotoxic and genotoxic potential of dopamine, J. Neurosci. Res., 1999, 55, 659–665 Graham D.G., Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones, Mol. Pharmacol., 1978, 14, 633–643 Halliwell B., Gutteridge J.M., The importance of free radicals and catalytic metal ions in human diseases, Mol. Aspects Med., 1985, 8, 89–193 Dexter D.T., Wells F.R., Agid F., Agid Y., Lees A.J., Jenner P., et al., Increased nigral iron content in postmortem parkinsonian brain, Lancet, 1987, 2, 1219–1220 Jenner P., Olanow C.W., Oxidative stress and the pathogenesis of Parkinson’s disease, Neurology, 1996, 47(Suppl. 3), S161–170 Langston J.W., Ballard P.A.Jr., Parkinson’s disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, N. Engl. J. Med., 1983, 309, 310 Ramsay R.R., Dadgar J., Trevor A., Singer T.P., Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP, Life Sci., 1986, 39, 581–588 Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D., Mitochondrial complex I deficiency in Parkinson’s disease, Lancet, 1989, 333, 1269 Bolaños J.P., Peuchen S., Heales S.J., Land J.M., Clark J.B., Nitric oxide-mediated inhibition of the mitochondrial respiratory chain in cultured astrocytes, J. Neurochem., 1994, 63, 910–916 Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., et al., Deficiencies in complex I subunits of the respiratory chain in Parkinson’s disease, Biochem. Biophys. Res. Commun., 1989, 163, 1450–1455 Lindroos M.M., Majamaa K., Tura A., Mari A., Kalliokoski K.K., Taittonen M.T., et al., m.3243A>G mutation in mitochondrial DNA leads to decreased insulin sensitivity in skeletal muscle and to progressive beta-cell dysfunction, Diabetes, 2009, 58, 543–549 Powers W.J., Videen T.O., Markham J., Black K.J., Golchin N., Perlmutter J.S., Cerebral mitochondrial metabolism in early Parkinson’s disease, J. Cereb. Blood Flow Metab., 2008, 28, 1754–1760 Almeida A., Almeida J., Bolaños J.P., Moncada S., Different responses of astrocytes and neurons to nitric oxide: the role of glycolytically generated ATP in astrocyte protection, Proc. Natl. Acad. Sci. USA, 2001, 98, 15294–15299 Almeida A., Moncada S., Bolaños J.P., Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway, Nat. Cell Biol., 2004, 6, 45–51 Cohen S.S., Scott D.B., Gluconokinase and the oxidative path for glucose-6-phosphate utilization, Nature, 1950, 166, 781–782 Filosa S., Fico A., Paglialunga F., Balestrieri M., Crooke A., Verde P., et al., Failure to increase glucose consumption through the pentosephosphate pathway results in the death of glucose-6-phosphate dehydrogenase gene-deleted mouse embryonic stem cells subjected to oxidative stress, Biochem. J., 2003, 370, 935–943 Borghammer P., Perfusion and metabolism imaging studies in Parkinson’s disease, Dan. Med. J., 2012, 59, B4466 De Rosa A., Criscuolo C., Mancini P., De Martino M., Giordano I.A., Pappatà S., et al., Genetic screening for LRRK2 gene G2019S mutation in Parkinson’s disease patients from Southern Italy, Parkinsonism Relat. Disord., 2009, 15, 242–244 Volonté M.A., Garibotto V., Spagnolo F., Panzacchi A., Picozzi P., Franzin A., et al., Changes in brain glucose metabolism in subthalamic nucleus deep brain stimulation for advanced Parkinson’s disease, Parkinsonism Relat. Disord., 2012, 18, 770–774 Henchcliffe C., Shungu D.C., Mao X., Huang C., Nirenberg M.J., Jenkins B.G., et al., Multinuclear magnetic resonance spectroscopy for in vivo assessment of mitochondrial dysfunction in Parkinson’s disease, Ann. NY Acad. Sci., 2008, 1147, 206–220 Ahmed S.S., Santosh W., Kumar S., Christlet H.T., Metabolic profiling of Parkinson’s disease: evidence of biomarker from gene expression analysis and rapid neural network detection, J. Biomed. Sci., 2009, 16, 63 Zheng B., Liao Z., Locascio J.J., Lesniak K.A., Roderick S.S., Watt M.L., et al., PGC-1α, a potential therapeutic target for early intervention in Parkinson’s disease, Sci. Transl. Med., 2010, 2, 52ra73 Bassil F., Fernagut P.O., Bezard E., Meissner W.G., Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?, Prog. Neurobiol., 2014, 118C, 1–18 Heales S.J., Davies S.E., Bates T.E., Clark J.B., Depletion of brain glutathione is accompanied by impaired mitochondrial function and decreased N-acetyl aspartate concentration, Neurochem. Res., 1995, 20, 31–38 Herken H., Neurotoxin-induced impairment of biopterin synthesis and function: initial stage of a Parkinson-like dopamine deficiency syndrome, Neurochem. Int., 1990, 17, 223–238 Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., et al., Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia, Ann. Neurol., 1994, 36, 348–355 Dexter D.T., Sian J., Rose S., Hindmarsh J.G., Mann V.M., Cooper J.M., et al., Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease, Ann. Neurol., 1994, 35, 38–44 Russell R.L., Siedlak S.L., Raina A.K., Bautista J.M., Smith M.A., Perry G., Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease, Arch. Biochem. Biophys., 1999, 370, 236–239 Martins R.N., Harper C.G., Stokes G.B., Masters C.L., Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer’s disease may reflect oxidative stress, J. Neurochem., 1986, 46, 1042–1045 Meijer A.E., The pentose phosphate pathway in skeletal muscle under patho-physiological conditions. A combined histochemical and biochemical study, Prog. Histochem. Cytochem., 1991, 22, 1–118 Gupte S.A., Glucose-6-phosphate dehydrogenase: a novel therapeutic target in cardiovascular diseases, Curr. Opin. Investig. Drugs, 2008, 9, 993–1000 Ursini M.V., Parrella A., Rosa G., Salzano S., Martini G., Enhanced expression of glucose-6-phosphate dehydrogenase in human cells sustaining oxidative stress, Biochem. J., 1997, 323, 801–806 Ninfali P., Guidi L., Aluigi G., Biagiotti E., Del Grande P., High glucose-6-phosphate dehydrogenase activity contributes to the structural plasticity of periglomerular cells in the olfactory bulb of adult rats, Brain Res., 1999, 819, 150–154 Braak H., Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., Braak E., Staging of brain pathology related to sporadic Parkinson’s disease, Neurobiol. Aging, 2003, 24, 197–211 Kirby J., Halligan E., Baptista M.J., Allen S., Heath P.R., Holden H., et al., Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS, Brain, 2005, 128, 1686–1706 Cosentino C., Grieco D., Costanzo V., ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair, EMBO J., 2011, 30, 546–555 Davies P., Moualla D., Brown D.R., Alpha-synuclein is a cellular ferrireductase, PLoS One, 2011, 6, e15814 Bendor J.T., Logan T.P., Edwards R.H., The function of alpha-synuclein, Neuron, 2013, 79, 1044–1066 Bellucci A., Collo G., Sarnico I., Battistin L., Missale C., Spano P., Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation, J. Neurochem., 2008, 106, 560–577 Fornai F., Schlüter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., et al., Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alphasynuclein, Proc. Natl. Acad. Sci. USA, 2005, 102, 3413–3418 Rodriguez-Araujo G., Nakagami H., Hayashi H., Mori M., Shiuchi T., Minokoshi Y., et al., Alpha-synuclein elicits glucose uptake and utilization in adipocytes through the Gab1/PI3K/Akt transduction pathway, Cell. Mol. Life Sci., 2013, 70, 1123–1133 Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., et al., Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease, Nat. Med., 1999, 5, 1403–1409 Fountaine T.M., Venda L.L., Warrick N., Christian H.C., Brundin P., Channon K.M., et al., The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons, Eur. J. Neurosci., 2008, 28, 2459–2473 Adamczyk A., Czapski G.A., Kaźmierczak A., Strosznajder J.B., Effect of N-methyl-D-aspartate (NMDA) receptor antagonists on alphasynuclein-evoked neuronal nitric oxide synthase activation in the rat brain, Pharmacol. Rep., 2009, 61, 1078–1085 Adamczyk A., Kaźmierczak A., Czapski G.A., Strosznajder J.B., Alphasynuclein induced cell death in mouse hippocampal (HT22) cells is mediated by nitric oxide-dependent activation of caspase-3, FEBS Lett., 2010, 584, 3504–3508 Clancy R.M., Levartovsky D., Leszczynska-Piziak J., Yegudin J., Abramson S.B., Nitric oxide reacts with intracellular glutathione and activates the hexose monophosphate shunt in human neutrophils: evidence for S-nitrosoglutathione as a bioactive intermediary, Proc. Natl. Acad. Sci. USA, 1994, 91, 3680–3684 Bolaños J.P., Delgado-Esteban M., Herrero-Mendez A., Fernandez-Fernandez S., Almeida A., Regulation of glycolysis and pentosephosphate pathway by nitric oxide: impact on neuronal survival, Biochim. Biophys. Acta, 2008, 1777, 789–793 Mejías R., Villadiego J., Pintado C.O., Vime P.J., Gao L., Toledo-Aral J.J., et al., Neuroprotection by transgenic expression of glucose-6-phosphate dehydrogenase in dopaminergic nigrostriatal neurons of mice, J. Neurosci., 2006, 26, 4500–4508 Opperdoes F.R., Michels P.A., Enzymes of carbohydrate metabolism as potential drug targets, Int. J. Parasitol., 2001, 31, 482–490